The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of pegylated liposomal doxorubicin and lapatinib in the treatment of metastatic breast cancer (MBC): Final results.
Mary E. Cianfrocca
Research Funding - GlaxoSmithKline
Virginia G. Kaklamani
No relevant relationships to disclose
Steven T. Rosen
No relevant relationships to disclose
Jamie H. Von Roenn
No relevant relationships to disclose
Alfred Rademaker
No relevant relationships to disclose
Deborah A. Smith
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Stephen D. Rubin
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Caitlin Meservey
No relevant relationships to disclose
Regina Uthe
Consultant or Advisory Role - GlaxoSmithKline
William John Gradishar
Consultant or Advisory Role - GlaxoSmithKline